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Abstract
Background—C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1) and E-selectin are systemic inflammatory markers (IM) that
positively correlate with cardiovascular (CV) risk. Despite the known CV effects of atypical
antipsychotics, there is limited prospective data on IM changes during treatment.
Methods—IM outcomes were compared between antipsychotic treatment groups in the CATIE
Schizophrenia Trial phase 1 using subjects with laboratory assessments at baseline and 3 months
(n=789).
Results—There were significant treatment differences in CRP, E-selectin and ICAM-1 at 3
months, with a differential impact of baseline values on the CRP and ICAM-1 results. In overall
comparisons, quetiapine and olanzapine had the highest median levels for CRP, and olanzapine for
E-selectin and ICAM-1. Olanzapine was significantly different after baseline adjustment than
perphenazine (p=0.001) for E-selectin, and, in those with low baseline CRP (< 1 mg/L),
olanzapine was significantly different than perphenazine (p<0.001), risperidone (p<0.001) and
ziprasidone (p=0.002) for CRP. Perphenazine had the lowest 3-month ICAM-1 levels in subjects
with baseline ICAM-1 above the median, but the differences were not statistically significant vs.
olanzapine (p=0.010), quetiapine (p=0.010) and risperidone (p=0.006) after controlling for
multiple comparisons. The 18-month repeated measures CRP analysis confirmed the significantly
higher values for olanzapine in those with low baseline CRP.
Conclusions—This analysis provides further evidence for differential antipsychotic metabolic
liabilities as measured by changes in systemic inflammation. CRP may emerge as a useful target
for CV risk outcomes in schizophrenia patients.
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Introduction
Schizophrenia is associated with twofold greater cardiovascular (CV) mortality (1), with life
expectancies 25–30 years less than expected (2). Modifiable risk factors and undertreatment
of CV risks (e.g. dyslipidemia) contribute to this public health problem (3). Increasingly,
consensus panels insist that treatment of schizophrenia patients addresses medical illness to
minimize common causes of excess mortality, especially CV disease (4).
Cardiovascular risk prediction has been greatly enhanced by the development of algorithms
derived from prospective trials, such as the Framingham Heart Study (FHS) (5). Therapy for
modifiable risk factors is crucial to risk reduction and focuses on decreasing low-density
lipoprotein (LDL) cholesterol; however, there are aspects of CV risk not captured by
cholesterol markers. Particularly problematic is the fact that 20% of FHS subjects
experienced major CV events without evident major risk factors (6), that 46% of CV events
in the Women’s Health Study occurred in those with serum LDL <130 mg/dL (7), and the
lack of correlation between baseline LDL and myocardial infarction (MI) risk during statin
treatment (8).
The search for means to refine CV risk assessment has centered on inflammatory markers
(IM) such as intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1
(VCAM-1), E-selectin, and C-reactive protein (CRP). Underlying this focus is evidence that
atherosclerotic disease is a chronic inflammatory state involving components of vascular
tissue (endothelial cells, smooth muscle cells) (9). Physiological stresses and inflammatory
cell recruitment are the primary causes of vascular injury, and precede changes in most
markers of vascular inflammation. The first step in monocyte recruitment is the presentation
of E-selectin on endothelial cell surfaces in response to cytokines, oxidative stress from
mechanical injury (e.g. turbulence, shear), or from phospholipids such as LDL and its
oxidative byproducts (10). E-selectin binds to selective receptors on lymphocyte surfaces,
slowing their movement along the endothelial surface (11). Subsequent adhesion of immune
cells to vascular endothelium is mediated by increased expression of cellular adhesion
molecules such as ICAM-1 and VCAM-1, the upregulation of which also occurs as a
response to mechanical or oxidative stress (9,12). The expression of ICAM-1 appears more
sensitive to LDL and oxidative LDL byproducts than mechanical injury, while VCAM-1
expression is increased by disturbed flow, other cytokines, and cholesterol (13,14). Since
these three markers have limited expression in normal endothelium, increases in soluble
forms measured in plasma serve as atherosclerosis markers (15).
Elevated IM levels are seen in various states associated with increased CV risk, including
metabolic disturbances in glucose-insulin homeostasis (15–17). Serum ICAM-1 and
VCAM-1 levels are elevated in patients with coronary heart disease (18), with higher
ICAM-1 levels predictive of greater CV risk (19), and increased levels of both ICAM-1 and
VCAM-1 associated with greater carotid atherosclerotic disease burden (20). Importantly,
serum levels of soluble E-selectin and ICAM-1 positively correlate with central adiposity,
and successful lifestyle modification that decreases body mass also lowers levels of both
markers (21), and of C-reactive protein (CRP) (22).
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CRP is a circulating acute phase reactant produced in hepatic cells in response to
interleukin-6 and leptin, and also in arterial smooth muscle cells, with the highest expression
in areas of atherosclerotic plaque (23). While CRP is an inflammatory marker, it accentuates
atherosclerotic injury through multiple mechanisms (24) including binding to, and
subsequent interference with leptin’s activity at target receptors (25). The CV risk associated
with CRP is continuous, but risk stratification typically divides patients into tertiles: <1 mg/
L (lowest risk), 1–3 mg/L, and >3 mg/L. The highest tertile is associated with twofold
greater risk (RR 1.9; 95% CI 1.5–2.3) for nonfatal MI and CV death compared to the lowest
tertile after controlling for traditional factors. Markedly elevated values (>>10 mg/L) are
typically ignored and repeated later, as they may reflect acute conditions (e.g. infection) and
not baseline systemic inflammation levels (26). Persistent values >15 mg/L are rarely
encountered.
CRP quantification of using high sensitivity assays (hS-CRP) has shown superior predictive
power by itself than other IM (27), and the use of CRP provides added CV risk information
after controlling for traditional CV risk factors (7). In global risk models, hS-CRP is second
to systolic blood pressure and ahead of smoking as a CV risk predictor (28,29). The hS-CRP
results from large statin trials also question whether the CV benefits from lipid reduction are
driven by LDL changes or changes in CRP. Patients in a large randomized pravastatin vs.
atorvastatin trial with lower post-treatment CRP experienced fewer CV events than those
with higher CRP, regardless of LDL levels (30); moreover, agents which reduce LDL but
increase CRP (e.g. hormone replacement therapy) are associated with increased CV risk.
Convincing evidence for CRP as a mediator of CV risk has also been recently demonstrated
by results of the JUPITER trial. This randomized, placebo-controlled study found that statin-
induced CRP reduction was associated with significantly reduced CV event risk among
individuals with low baseline LDL (<130 mg/dL) but elevated CRP (≥2 mg/L) (31).
Despite the cardiometabolic risk associated with atypical antipsychotics, there is limited
published information on IM changes in response to antipsychotics with varying metabolic
liabilities. Preliminary data from a 5-month randomized risperidone vs. olanzapine trial
(n=42) found few patients with CRP >1 mg/L at any time point, and no between-drug
differences in CRP at any time point by independent t-test, or repeated measures analysis of
drug by time effects (32). However, a cross-sectional analysis of IM in 88 chronic
schizophrenia patients found higher mean CRP levels: clozapine 5.2±5.0 mg/L (n=29),
olanzapine 4.9±2.9 mg/L (n=29), typical antipsychotics 6.9±4.2 mg/L (n=30) (33). While
varying assay methods and subject demographics create difficulties in comparing CRP
levels between the two trials, CRP levels in the latter study correlated positively with central
adiposity and negatively with serum high-density lipoprotein (HDL) cholesterol levels, thus
demonstrating a consistent association between dysmetabolic states and increased systemic
inflammation.
The large sample and randomized nature of the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) Schizophrenia Trial phase 1 offers an opportunity to examine
antipsychotic effects on IM. The a priori hypothesis for this analysis is that there will be
significant between-drug differences in 3-month IM changes. Secondary analyses will
examine the association between IM changes and changes in individual metabolic
parameters.
Methods and Materials
Recruitment and enrollment criteria for the CATIE Schizophrenia Trial have been
previously described (34). Blood for IM was collected at screening and months 3, 6, 12, 18
and end of phase 1 (up to 18 months). Plasma was analyzed for soluble levels of CRP,
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ICAM-1, VCAM-1 and E-selectin on the Bioplex Xmap system (Bio Rad) using Luminex
bead-based assays. CRP levels were determined with an Invitrogen/Biosource (Carlsbad,
CA) kit as a single-plex assay with initial plasma dilution of 1:500 per the manufacturer's
instructions. Subject samples were compared to a serial 1:3 dilution standard curve of CRP
(10.97–8,000 pg/mL). ICAM-1, VCAM-1 and E-selectin levels were determined with a
Linco/Millipore (Chicago, IL) kit as a three-plex assay with initial plasma dilution of 1:100
per the manufacturer’s instructions. Subject samples were compared to a serial 1:5 dilution
standard curve of ICAM-1, VCAM-1 and E-selectin (80–250,000 pg/mL). For both assays,
four-point logarithmic curve fits were performed on all standard curves of expected
concentration versus median fluorescence intensity per bead set. The minimum detectable
level of CRP was 2 pg/mL, of ICAM-1 9 pg/mL, of VCAM-1 16 pg/mL, and of E-selectin
79 pg/mL. Seventy-four distinct assays were performed over a 4-month period with the
following median interassay coefficients of variation (6 test measurements per run):
CRP-4.1%, ICAM-3.8%, VCAM-5.5% and E-selectin-3.7%. Reported final results were
corrected for the initial sample dilution in either assay. Samples with results outside this
range were assayed after further dilution, and results were extrapolated.
The primary analysis was conducted in subjects with non-extrapolated IM values at baseline
and 3 months. The 3-month value was chosen as the time point for the analyses to maximize
subject retention, while providing a physiologically meaningful period to assess
antipsychotic impact. E-selectin, ICAM-1, VCAM-1 are sensitive to prandial effects, so only
subjects with fasting laboratory measures (last meal >8 hours) at baseline and 3 months
could be used (n=268). CRP has a half-life of 19 hours, with limited diurnal and prandial
effects (36), so all non-extrapolated specimens were used in the primary analyses, regardless
of fasting status (n=789) except for 2 samples with CRP ≥15 mg/L, due to their probable
association with acute infectious or inflammatory processes. Only CRP and E-selectin had
extrapolated data. A supportive analysis included the extrapolated data, but with values
truncated to the lowest or highest nonextrapolated value. The exclusion of extrapolated
values from the primary analysis removed 28 subjects (3.4% of 817) for CRP and 72
subjects (27% of 268) for E-selectin. As a result of the skewed distribution for CRP, E-
selectin, and ICAM-1, the data for these IM underwent log transformation prior to analysis.
Analysis of variance (ANOVA) and Spearman correlations were used to examine the
relationship between IM levels and metabolic syndrome (MS) criteria. Initial treatment
group comparisons of IM at baseline and 3 months were made using (ANOVA) (4 df).
Adjusted comparisons of IM at 3 months were performed using a 4 df Analysis of
Covariance (ANCOVA), which adjusted for baseline IM values and allowed for
consideration of age, gender, other baseline antipsychotic medications, and two CATIE
design measures (study entrance after the ziprasidone treatment option was added, and
having tardive dyskinesia at baseline) (35). For all treatment group comparisons, if the
analysis yielded an overall treatment group difference (p<0.05), the 10 possible pairwise
comparisons between treatments were performed with a Bonferroni correction, yielding an
α of .05/10 = 0.005 as the threshold for significance. Due to the conservative nature of the
Bonferroni correction, p-values between 0.005 and 0.01 are noted for the reader’s discretion.
Potential interactions between baseline covariates and treatment group were explored and, if
identified, treatment groups were compared within levels of the covariate using additional
ANCOVA models. If an interaction was identified between baseline level of CRP and
treatment group, treatment comparisons were made with additional models for those with
low (<1 mg/L) and moderate/high (≥1 mg/L) baseline CRP values. This cutoff point was
selected a priori because of its clinical significance to CV risk. Unlike CRP, for which well-
established risk cutpoints exist based on population norms, these do not exist for the other
markers. Therefore, when necessary, other cutpoints were based on the sample median.
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Because IM data at 3 months was not available for all randomized patients, a sensitivity
analysis of the primary treatment group comparison was performed, and ANCOVA models
further adjusted for baseline covariates that were found to be predictive of patient dropout.
These significant covariates (p<0.10) were identified with logistic regression models that
predicted which patients had baseline and 3-month laboratory data, both overall and limited
to fasting samples.
The ability to use all gathered data for CRP permitted a secondary mixed model analysis to
be performed using non-extrapolated values collected at any post-baseline visit, combined
into time intervals corresponding to 3, 6, 12 and 18 months as in prior CATIE metabolic
analyses (37). Due to the paucity of fasting samples, mixed model analyses could not be
performed for the other markers. CRP change from baseline was compared across treatment
groups with a mixed model including terms for baseline CRP, time (treated as a
classification variable), and terms representing baseline-by-time, treatment-by-time, and
baseline-bytreatment interactions. A random subject effect and a spatial power covariance
structure were used to adjust standard errors for correlation of observations within
individual. No treatment-bytime interaction was found, and therefore treatment effects were
averaged over visits for comparisons.
Results
Subjects with fasting values at baseline and 3-month assessments (fasting cohort) were
similar on all demographic variables with subjects who had nonfasting laboratory values at
one or both time points (Table 1). Those with baseline and 3-month CRP values were also
similar to other CATIE phase 1 subjects, but were older (+1.4 years) than those without
follow-up CRP (T1,347=2.25, p=0.025). At 3 months, median CRP levels were significantly
higher in patients who met MS criteria (Table 2), and higher CRP values positively
correlated with greater number of MS criteria (rS=0.27, p<0.001) (Figure 1). Among the
other IM, only fasting E-selectin levels were correlated with greater number of MS criteria
(rS=0.15, p=0.027).
The olanzapine and quetiapine groups had the highest median CRP at the 3-month
assessment, and the greatest numerical increase from baseline (Table 3). In the primary
analysis, there was a significant overall treatment difference in 3-month CRP values after
adjustment for the significant effect of baseline CRP and gender (p=0.013). Pairwise
comparison revealed a statistically significant difference between olanzapine and risperidone
(p=0.004). Given the differential impact of baseline CRP on the relationship between
treatment and 3-month outcome (F4,779=2.56, p=0.037), the same ANCOVA model was
repeated separately for those subjects with low baseline CV risk (CRP <1 mg/L, n=500) and
higher risk (CRP ≥1 mg/L, n=289). For subjects with lower baseline CRP, pairwise
treatment comparison found significant differences for olanzapine vs. perphenazine
(p<0.001), vs. risperidone (p<0.001), and vs. ziprasidone (p=0.002) (see Table 4). The
overall test of treatment difference was not significant for patients with higher CRP values at
baseline (p=0.511). The supportive analysis, including extrapolated values truncated at the
lower or higher nonextrapolated value, did not find a significant overall treatment difference
for CRP (F4,810=1.98, p=0.095). However, for those subjects with low baseline risk,
significant differences (with Bonferroni correction) for olanzapine vs. perphenazine
(T231=3.37, p=0.001) and vs. risperidone (T245=3.39, p=0.001), but not ziprasidone
(T195=2.46, p=0.014), were confirmed.
There were also significant treatment differences for fasting E-selectin in the 3-month
analysis. Olanzapine and quetiapine patients had the highest median E-selectin value at 3
months, and treatment pairwise comparison was statistically significant for olanzapine vs.
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perphenazine (p=0.001) and noteworthy for olanzapine vs. risperidone (p=0.010), although
not significant after Bonferroni correction (Table 3). The supportive analysis of E-selectin
outcomes including truncated extrapolated values confirmed the significant between-group
differences for olanzapine vs. perphenazine (T97=2.91, p=0.004), and found noteworthy
differences for olanzapine vs. risperidone (T116=2.65, p=0.009), for quetiapine vs.
perphenazine (T91=2.80, p=0.006) and for quetiapine vs. risperidone (T109=2.72, p=0.007).
Due to a significant effect for TD status in this model (F1,201=4.67, p=0.032), all
comparisons involving perphenazine excluded patients with TD.
For ICAM-1, there were significant differences for perphenazine vs. quetiapine (p=0.002),
and vs. risperidone (p=0.001) and a noteworthy difference, but not significant after
Bonferroni correction, vs. olanzapine (p=0.006). As with CRP, there was a differential effect
of baseline ICAM-1 value on treatment effects (F4,258=2.87, p=0.024), with trends for
treatment differences occurring only in those patients with baseline ICAM-1 above the
median (≥273 ng/ml); however, these differences fell short of statistical significance due to
Bonferroni correction: perphenazine vs. quetiapine (p=0.010), vs. olanzapine (p=0.010), and
vs. risperidone (p=0.006) (Table 4). There were no significant between group differences for
VCAM-1 in the 3-month analysis after adjusting for baseline levels (Table 3).
In a supportive logistic regression analysis, age, white race, and baseline total Positive and
Negative Syndrome Scale (PANSS) score were found to be significant predictors of having
baseline and 3-month laboratory values, while gender and baseline PANSS score were
associated with having fasting laboratory values at baseline and 3 months. Inclusion of these
covariates in the ANCOVA models revealed that none of the predictors were significantly
associated with change in IM at 3 months (p>0.05 for all), yielding results consistent with
the original findings.
Given the association between metabolic dysfunction and IM, we examined the Spearman
correlation between 3-month changes in each of the four IM and changes from baseline in
metabolic parameters: adiposity measures (waist circumference, body mass index {BMI}),
systolic and diastolic BP, fasting lipids (total cholesterol, triglycerides and HDL) and fasting
glucose. Only data from the fasting cohort was used for the 3 IM that are sensitive to
prandial effects (E-selectin, ICAM-1, VCAM-1) and for correlations between CRP and
metabolic parameters that require fasting samples (glucose, lipids). Among these
correlations, there were small associations between 3-month change in E-selectin with waist
circumference (rS=0.20, p=0.007) and BMI (rS=0.26, p<0.001). CRP itself does not require
fasting samples, so all available data (fasting and random samples) were used in the
correlation analysis for change in CRP and change in adiposity and blood pressure
measures. The 3-month change in CRP was weakly correlated with both change in BMI
(rS=0.073, p=0.044) and change in HDL (rS=−0.11, p=0.004). After adjusting for baseline
IM value, the correlations with CRP and E-selectin were nonsignificant.
To account for prior antipsychotic medications, especially the large number taking
olanzapine (24%) or risperidone (21%) at study baseline who were randomized to the same
medication in phase 1 (8% and 5%, respectively), prior antipsychotic was considered as a
potential covariate in the rank ANCOVA model for each IM at 3-months. However, in all
cases, it was neither statistically significant nor did it alter the treatment effects.
The repeated measures analysis of change in CRP up to 18 months found an overall
significant treatment effect over time (F4,1086=2.86; p=0.023), with pairwise comparisons
revealing a trend for higher values in olanzapine versus perphenazine (T1,058=2.57;
p=0.010). As with the 3-month analysis, an interaction between treatment and baseline CRP
was identified (F4,986=4.68; p=0.001), and treatment comparisons were made stratifying on
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baseline CRP risk level. There were significant between group differences among 694
subjects with CRP values <1mg/L at baseline (F4,671=4.51, p=0.001) (Figure 2, Table 5).
Pairwise treatment comparisons found significant differences for olanzapine vs.
perphenazine (T657=3.83, p<0.001) and vs. ziprasidone (T681=3.03, p=0.003). There was no
treatment difference in the cohort with baseline CRP ≥1 mg/L (F4,387=0.25; p=0.910,
n=394).
Discussion
Presented here is the first analysis of data from a randomized study to examine the
comparative impact of multiple antipsychotic therapies on changes in systemic
inflammation. While certain metabolic effects from antipsychotic exposure are known, this
is the first attempt to examine other pathophysiological elements that may underlie excess
CV morbidity and mortality in chronic schizophrenia patients, and may be associated with
antipsychotic treatment, particularly second-generation agents. The importance of CRP for
CV risk prediction has been firmly established (31), but this is the first data set to confirm
that atypical antipsychotic therapy may have differential effects on other IM, with
olanzapine consistently emerging as a treatment with higher risk across several IM. Over the
3-month time frame, only the VCAM-1 results did not reveal any differences between
antipsychotics.
As seen in larger samples (38), there is a correlation among CATIE subjects between
increasing numbers of MS components and measures of systemic inflammation, specifically
levels of E-selectin and CRP, so the expectation is that antipsychotics which adversely affect
MS risk will result in concomitant changes in these IM. Olanzapine is associated with
deleterious metabolic effects (39), while earlier CATIE analyses indicated that
perphenazine, risperidone and ziprasidone are relatively more benign (37), so the findings
seen here are consistent with the metabolic properties of these medications. Little historical
metabolic outcomes data was available for perphenazine, but the findings from this and
other CATIE studies confirm that perphenazine treatment is associated with reduction in
markers of CV risk, including CRP and E-selectin (34,37). There were also noteworthy
numerical differences when 3-month ICAM-1 levels for perphenazine were compared to
those of other treatments among subjects with high baseline ICAM-1 levels, although these
fell short of significance due to Bonferroni correction. It is also worth pointing out that the
quetiapine cohort the numerically highest 3-month VCAM-1 level and the numerically
highest 3-month CRP level (which it shared with olanzapine), and was the only treatment in
which the median E-selectin level at 3 months was not lower than baseline.
Aside from the link between psychotropic-induced weight gain and central histamine H1
antagonism (40), with additive effects of 5HT2C antagonism (or 5HT2C receptor
polymorphisms) for medications with high H1 affinity (41,42), the mechanisms underlying
antipsychotic-induced dyslipidemia and hyperglycemia are unclear; nonetheless, these data
indicate that alterations in IM are likely to accompany antipsychotic changes. The absence
of strong correlations between change in any IM and change in metabolic variables may be
due to a number of factors. Small sample sizes for the fasting analyses are one contributor.
As shown in prior 3-month CATIE metabolic analyses (37), the mean changes in metabolic
syndrome parameters across all drug arms was modest (waist circumference −0.4 – +0.7
inches; systolic BP −2.9 – −0.5 mmHg; diastolic BP −1.4 – +0.1 mmHg; HDL −2.3 – −0.1
mg/dL; fasting glucose −1.1 – +4.7 mg/dL; fasting triglycerides −32.1 – +21.5 mg/dL), so
these small changes individually may not correlate with IM alterations; however, the fact
that significant associations were found between certain IM and medication suggests that the
combined effects of antipsychotic-induced changes on multiple metabolic parameters, or
possibly direct drug effects on cytokine regulation, can accrue significant physiological
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impact. Given the impact of CRP on metabolic functioning, the findings of these analyses
also open the door to the possibility that certain antipsychotic metabolic effects are mediated
through inflammatory cytokines such as CRP (24). Further research might clarify why
significant antipsychotic effects on CRP were only seen in those with low baseline CRP,
while greater effects on ICAM-1 were only found for those with high baseline ICAM-1.
These data clearly indicate that, among subjects with lower CRP levels, changes in
antipsychotic therapy can improve or worsen CV risk as early as 3 months after treatment
initiation through changes in CRP; moreover, there may be concomitant changes in other
IM, the clinical significance of which is still being elucidated. Clinicians are thus provided
with another reason to be judicious in the use of antipsychotics, and to be diligent in
metabolic monitoring. For patients with metabolic abnormalities who cannot switch
medications, the limited studies on statin treatment in dyslipidemic schizophrenia patients
show expected improvements in LDL cholesterol (43,44). In general population studies for
patients with type 2 DM or coronary heart disease, statin therapy has been proven to reduce
LDL cholesterol and IM (15,30). Unfortunately, the published literature is silent on whether
statin treatment achieves comparable IM reduction in antipsychotic treated patients. Given
the association between insulin resistance, central adiposity and systemic inflammation (45–
47), medications that improve insulin sensitivity have been proposed as one way to address
elevated IM in the context of antipsychotic mediated metabolic dysfunction; however, two
placebo-controlled studies of adjunctive metformin during olanzapine treatment failed to
establish any significant impact on CRP (48,49), although the metabolic benefits noted in
some trials (50) might certainly influence other IM.
One limitation of this analysis derives from the fact that, at study baseline, nearly half of
CATIE subjects were taking either olanzapine or risperidone, and 13% were randomized to
the same medication in phase 1, diminishing the extent of any change from baseline noted in
those medication arms. In addition, analyses of fasting IM, and in particular E-selectin, were
hindered by small sample sizes, as were stratified analyses used to explore treatment effects
in the presence of interaction with baseline IM values. In general, there was also reduced
power to find differences between ziprasidone and the other treatments due to its addition to
CATIE after 40% of subjects had been enrolled. While certain baseline variables were
predictive of drop-out, these did not have a significant influence on IM outcomes; however,
unequal subject attrition for assigned treatments may have injected some bias, as more data
was available for olanzapine-treated subjects than for other medication assignments. The
assay method employed for these analyses is used for research purposes only, so the
magnitude of any treatment effect found here may differ from that using other forms of
laboratory analysis.
Nonetheless, differences exist between various antipsychotics on measures of systemic
inflammation, and emerge after relatively brief exposure. When antipsychotic switching is
not an option, the available evidence points towards lifestyle modification and standard
pharmacotherapy as the best means to address elevated IM in the context of antipsychotic
therapy. For many patients with schizophrenia, the greatest impediments to effective
medical management of antipsychotic treatment are the failure to perform routine laboratory
monitoring (51) and undertreatment of common risk conditions (3). The present data not
only reinforce the need for aggressive metabolic monitoring during antipsychotic treatment,
but also foreshadow the importance of inflammation in our understanding of CV risk
changes during antipsychotic therapy (52).
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Distribution of Median and Interquartile Range for Inflammatory Marker Values According
to Number of Metabolic Syndrome (MS) Criteria at 3 months
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Repeated Measures Model of C-Reactive Protein (CRP) Changes After Adjustment for
Baseline CRP (Subjects With Baseline CRP < 1 mg/L)*
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Table 1
Demographics of CATIE Subjects with Baseline and 3-month Fasting ICAM-1, VCAM-1 and E-selectin
Values (Fasting Cohort), and Baseline and 3-Month C-Reactive Protein Values (CRP) *
Parameter FastingCohort CRP
Age 40.6 ± 11.1(N=268)
41.2 ± 10.8
(N=789)
Gender (% Male) 78.4%(N=268)
74.5%
(N=789)
Race (% White) 64.6%(N=268)
62.8%
(N=788)
Ethnicity (% Hispanic) 11.6%(N=268)
11.3%
(N=789)
Years of Education 12.3 ± 2.0(N=266)
12.1 ± 2.3
(N=785)

















Note: Table entries are Mean ± SD or %.
*
Excluding extrapolated data
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Table 2
Median Marker Levels (Interquartile Range) By Presence or Absence of Metabolic Syndrome Criteria† and
Smoking Status at 3 Months1
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Central Obesity: Male and waist circumference > 40 inches, or female and waist circumference > 35 inches
Elevated Triglycerides: Fasting triglycerides ≥ 150 mg/dL
Low HDL: Male and HDL <40 mg/dL, or female and HDL <50 mg/dL
Elevated Glucose: Fasting glucose ≥ 100 mg/dL or random glucose value ≥ 200 mg/dl, or on insulin or hypoglycemic medication
Elevated BP: ≥ 130/85 mm Hg or on antihypertensive medication
††
P-values based on ANOVA on the log transformation, except for VCAM-1, which was normally distributed and not transformed.
*
Metabolic syndrome diagnosis based on all subjects with sufficient data to be classified (i.e. met ≥ 3 criteria).
**
Patients were considered current smokers if they smoked five or more cigarettes daily over the previous week.
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Table 4
Median 3-Month Marker Levels and Change from Baseline (Interquartile Range) By Treatment Stratified on
Baseline Marker Level
CRP (mg/L) ICAM-1 (ng/mL)




Olanzapine (n=127) (n=75) (n=24) (n=46)
Level 0.61 (0.19–1.23) 1.27 (0.50–1.89) 221 (120–298) 305 (205–440)
Change 0.27 (−0.01–0.85) −0.72 (−1.29–0.13) 44 (−40–102) −174 (−260- −52)
Perphenazine (n=95) (n=48) (n=18) (n=33)
Level 0.31 (0.15–0.77) 1.31 (0.78–2.10) 194 (132–250) 241 (148–297)
Change 0.04 (−0.15–0.32) −0.39 (−1.08–0.18) 6 (−48–41) −190 (−339- −118)
Quetiapine (n=111) (n=69) (n=34) (n=31)
Level 0.51 (0.23–0.99) 1.23 (0.78–1.88) 197 (152–249) 299 (188–374)
Change 0.13 (−0.07–0.53) −0.44 (−1.27–0.29) 35 (−41–85) −118 (−188- −32)
Risperidone (n=109) (n=69) (n=36) (n=15)
Level 0.26 (0.12–0.78) 1.14 (0.54–1.94) 189 (146–279) 358 (199–550)
Change 0.04 (−0.09–0.46) −0.73 (−1.60–0.04) 7 (−36–100) −12 (−187–179)
Ziprasidone (n=58) (n=28) (n=23) (n=8)
Level 0.43 (0.14–0.87) 0.91 (0.41–2.19) 146 (91–237) 273 (179–448)
Change 0.11 (−0.16–0.38) −0.56 (−1.39- −0.09) 15 (−69–82) −113 (−195–40)
Overall Treatment
Difference†
Test Statistic; p-value F4,493=5.57; p<0.001* F4,282=0.82; p=0.511 F4,129=1.26; p=0.287 F3,119=3.82; p=0.012**
†
An ANCOVA on the log transformation was used to compare treatments. The adjusted models included the log transformation of the baseline IM
values, as well as gender in the CRP model and a ziprasidone cohort effect in the ICAM-1 model where baseline ≥ 273 ng/ml. These were the only
significant covariates of those considered for inclusion. E-Selectin and VCAM-1 are not included in table due to absence of significant treatment
by baseline interaction.
*
Between group comparisons at 3 months were statistically significant for olanzapine vs. perphenazine (T221=4.02, p<0.001), risperidone
(T235=3.57, p<0.001), and ziprasidone (T184=3.17, p=0.002).
**
Between group comparison at 3 months were numerically different (but not statistically significant with Bonferroni correction) for perphenazine
vs. olanzapine (T78=2.61, p=0.010), quetiapine (T63=2.60, p=0.010), and risperidone (T47=2.80, p=0.006). A significant ziprasidone cohort effect
was found for this model (F1,119=6.04, p=0.015). No significant differences were found between ziprasidone and the other treatments in the
ziprasidone cohort (N=63).
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Table 5
Sample Sizes by Visit and Treatment for Subjects with Baseline CRP < 1 mg/L
Visit 3 6 12 18
Olanzapine 154 114 83 71
Perphenazine 124 78 46 34
Quetiapine 143 89 60 40
Risperidone 144 97 71 53
Ziprasidone 81 46 35 20
TOTAL 646 424 295 218
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